Status:
UNKNOWN
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
Lead Sponsor:
Peking University People's Hospital
Conditions:
Acute Leukemia
CMV Viremia
Eligibility:
All Genders
18-65 years
Brief Summary
This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection
Detailed Description
According to the changes of molecular and gene expression in NK cells at different time points after infection, we want to find out the mechanism by which HCMV promotes the expansion of NKG2C + NK cel...
Eligibility Criteria
Inclusion
- AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation
- No severe organ dysfunction or failure
- Subjects must be capable of, and willing to provide written informed consent to participate in the study. Subjects unable to provide written informed consent by themselves may be consented through their legal representative.
Exclusion
- Participation in another industry-sponsored clinical study where treatment for CMV is already specified by the study protocol.
- Patients received other adoptive immunotherapy such as donor lymphocyte infusion (DLI), Epstein-Barr virus (EBV)-specific T cells and so on.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04298502
Start Date
January 1 2020
End Date
December 31 2021
Last Update
October 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Institute of Hematology
Beijing, Beijing Municipality, China, 100044